| ||
| ||
| Study: Hormone-blocking drug reduces breast-cancer risk The Seattle Times Diana Zuckerman, president of the Cancer Prevention and Treatment Fund, a patient-education group, said the results were promising but that women in the study were followed for only three years, too short to judge long-term effects from taking the drug ... See all stories on this topic » | ||
| Debate Continues on Use of PSA Testing for Early Detection of Prostate Cancer Journal of American Medical Association (subscription) The US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial reported no mortality benefit from combined screening with PSA testing and digital rectal examination (DRE) during a median follow-up of 11 years (Andriole GL et al. ... See all stories on this topic » | ||
| Roche's Avastin Delays Growth of Ovarian Cancer in Study San Francisco Chronicle Avastin, developed by Roche's South San Francisco, California-based Genentech unit, generated revenue of $6.2 billion last year as a treatment for colorectal, brain, lung and kidney tumors. It reached the market in 2004 as the first medicine cleared to ... See all stories on this topic » |
| ||
| Asbestos Lung Cancer Law Firms for the rights of asbestos victims ... Chinese Medicine treatment of Breast cancer, lung cancer, mesothelioma ... that they only receive payment when you do. There is no up-front cost to you. ... www.cancer-c.com/.../asbestos-lung-cancer-law-firms.html |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment